DME

According to the company, this Phase 1 dose escalations study will evaluate the safety and tolerability of intravitreal injection of IBI324 in subjects with DME.

Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.

The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.

Treatment and reduces burden of care, providing a treatment option for patients diagnosed with diabetic macular edema.

According to the company, new imaging options presenting opportunity for better outcomes for patients.

The findings could lead to a new understanding of unexplained causes of heritable retinal diseases.

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.

Physicians use a new administration method to treat patients diagnosed with noninfectious uveitis.

The ASRS See for a Lifetime See a Retina Specialist initiative will spotlight early detection and outline the importance of seeing a retina specialist.

During a presentation at the American Society of Retina Specialists 2022 annual meeting in New York, Bobeck S. Modjtahedi, MD, presented results of a study that examined the accuracy of tools for predicting the risk of vision-threatening diabetic retinopathy.

In a presentation at the American Society of Retina Specialists, Dimitra Skondra, MD, PhD, points out that the low-to-moderate doses of metformin carried the greatest potential benefit in a retrospective case-control study.

The University of Oklahoma Health Sciences Center has received an unrestricted grant from Research to Prevent Blindness for $575,000 over 5 years to support eye research conducted by the Department of Ophthalmology.

Charles Brodowski, MD, and Patrick Rapuano, MD, have been named co-chief residents at Wills Eye Hospital, and will lead the team of resident doctors on staff, focusing on training and recruitment while attending to their own medical resident duties.

Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.

The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.

The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.

According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular edema patients.

Faricimab is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

A team of investigators has found that a comparison of ranibizumab and aflibercept showed both drugs safe and effective for treating diabetic macular edema.

According to the company, the trial did not demonstrate efficacy on the key clinical endpoints and will not advance THR-687 to Part B of the trial. As a result, Oxurion will now shift its focus to the Phase 2 development program for THR-149, which recently demonstrated a compelling safety and efficacy profile for the treatment of patients with DME.

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

According to the company, the trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations.

Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.

During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.

Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.

Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.